News & Updates
Filter by Specialty:

Dabrafenib plus trametinib boasts high pathological response for stage III melanoma
12 Aug 2024
Pathological response rates are high for neoadjuvant dabrafenib plus trametinib among patients with stage III melanoma, but recurrence-free survival (RFS) rates are low, reports a study.